GlassScriptPhysician profile
Emily R Himes
NPI 1417272006
$2,541.30
in general payments reported to CMS, 2019-2025
22 companies · $816 in 2025
The $816 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $163 · 2021: $247 · 2022: $239 · 2023: $366 · 2024: $425 · 2025: $816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,508 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,507.53 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $480.75 | 2019-2025 | Tremfya |
| Amgen INC. | $357.56 | 2020-2025 | Otezla, Otezla, Enbrel |
| Sun Pharmaceutical Industries INC. | $262.51 | 2019-2025 | Winlevi, Blu-U, Odomzo |
| Abbvie INC. | $256.64 | 2019-2024 | |
| Pfizer INC. | $172.34 | 2019-2023 | |
| Ucb, INC. | $168.65 | 2023-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $154.67 | 2020-2025 | |
| Leo Pharma INC. | $153.31 | 2019-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $67.52 | 2023 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $63.89 | 2023-2025 | Zoryve |
| Genzyme Corporation | $61.89 | 2019-2025 | |
| Incyte Corporation | $57.06 | 2021-2025 | Opzelura |
| Almirall LLC | $48.41 | 2021 | |
| Organogenesis INC. | $45.99 | 2025 | Simplimax |
| Dermavant Sciences, INC. | $37.24 | 2023 | Vtama |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $33.28 | 2019-2020 | |
| Galderma Laboratories, L.P. | $27.38 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.72 | 2023 | Spevigo |
| Biofrontera INC. | $21.97 | 2025 | |
| Aclaris Therapeutics, INC. | $17.14 | 2019 | |
| Revance Therapeutics, INC. | $15.89 | 2024 | Daxxify |
| Merck Sharp & Dohme LLC | $13.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Himes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.